In this episode of Meeting Mic, we bring you pearls and perspectives from the 2022 ASCO Annual Meeting, as well as Healio’s top headlines from the meeting.

Stephen M. Ansell, MD, PhD, discusses efforts to identify new upfront treatment regimens to help extend OS in patients with relapsed or refractory classical Hodgkin lymphoma. :25

Lorenzo Cohen, PhD, shares his thought on the impact of acupuncture regimens on xerostomia and patients’ quality of life. 5:26

Bradley J. Monk, MD, discusses the results of a study on the use of rucaparib monotherapy among women with advanced ovarian cancer 10:37

Christopher Manz, MD, MSHP, provides an overview of the results of the randomized PROStep trial, which assessed whether remote patient-reported symptoms and passive activity monitoring could improve patient-clinician communication about symptoms and functional status of patients with cancer. 18:09

Luke Maese, DO, discusses the results of the Children’s Oncology Group AALL1931 study, its rationale, the potential implications of the findings and the questions that must be addressed in future research. 21:04    

Read the full coverage here:

https://www.healio.com/news/hematology-oncology/20220603/firstline-brentuximab-vedotin-regimen-extends-os-in-advanced-classical-hodgkin-lymphoma

https://www.healio.com/news/hematology-oncology/20220609/acupuncture-benefits-patients-with-radiationinduced-xerostomia

https://www.healio.com/news/hematology-oncology/20220606/rucaparib-shows-efficacy-as-firstline-maintenance-therapy-in-ovarian-cancer

https://www.healio.com/news/hematology-oncology/20220610/more-work-to-do-in-oncology-to-collect-useful-data-about-symptoms-functional-status

https://www.healio.com/news/hematology-oncology/20220611/intramuscular-recombinant-erwinia-asparaginase-active-safe-in-leukemia-lymphoma-subsets

Dostarlimab shows efficacy as curative-intent treatment in rectal cancer subset

Source: Cercek A, et al. Abstract LBA5. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.

Trastuzumab deruxtecan extends survival in HER2-low metastatic breast cancer

Source: Modi S, et al. Abstract LBA3. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.

Disclosures:

Ansell reports research funding to his institution from ADC Therapeutics; Affimed Therapeutics, AI Therapeutics, Bristol Myers Squibb, Regeneron, Seagen and Trillium Therapeutics, and honoraria from Research to Practice and WebMD.

Cohen reports no relevant financial disclosures.

Monk reports relationships with Clovis Oncology, Merck, Roche/Genentech and several other pharmaceutical companies.

Manz reports no relevant financial disclosures.

Maese reports consultant and speakers bureau roles with Jazz Pharmaceuticals.